文献速递免疫规划传染病防控与疫情报告妇幼与学校卫生

英格兰侵袭性B群脑膜炎球菌病患儿接种4CMenB(Bexsero®)疫苗的时机

Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England.
PubMed 文献 · Vaccine · 2022-02-08

该研究分析了英格兰2015年7月1日至2019年8月31日出生的276例实验室确诊B群脑膜炎球菌病患儿,评估4CMenB疫苗纳入国家婴儿免疫规划后的接种及时性。结果显示,发病前48/104(46.5%)的合格婴儿和28/77(36.6%)的≥1岁儿童存在未及时接种的情况;采用8周和12周短间隔程序可能为35/58(58.6%)在10至18周龄发病的婴儿额外提供一剂4CMenB。

要点

  • 确诊B群脑膜炎球菌病的婴幼儿中,相当比例在发病前未按程序接种4CMenB疫苗。
  • 48/104(46.5%)的合格婴儿在发病前有2剂接种机会,28/77(36.6%)的≥1岁儿童存在接种不足。
  • 8周和12周短间隔程序可能为35/58(58.6%)在10至18周龄发病的婴儿额外提供一剂4CMenB。

核心结论

  • 高比例的实验室确诊B群脑膜炎球菌病婴幼儿在发病前未接种其计划的4CMenB疫苗。
  • 婴儿基础免疫采用4周短间隔程序有可能提供更早的B群脑膜炎球菌病保护。

研究设计与样本

  • 研究纳入2015年7月1日至2019年8月31日期间出生、且在2015年9月1日至2019年8月31日四个监测年度内发生B群脑膜炎球菌病的儿童。
  • 英格兰公共卫生署(PHE)对英格兰侵袭性脑膜炎球菌病进行监测,本研究分析其中实验室确诊的B群脑膜炎球菌病患儿。

主要发现

  • 共276例实验室确诊B群脑膜炎球菌病患儿,其中36例婴儿年龄过小不符合接种条件,59例在发病前符合接种1剂4CMenB的条件,104例符合接种2剂的条件,77例符合接种3剂的条件。
  • 发病前,104例符合接种2剂条件的婴儿中48例(46.5%)存在2剂4CMenB接种机会;77例≥1岁儿童中28例(36.6%)接种不足,共存在41次接种机会。
  • 与现行8周和16周程序相比,采用8周和12周短间隔程序有可能为35/58例(58.6%)在10至18周龄发病的婴儿额外提供一剂4CMenB。

临床怎么用

  • 作者认为,婴儿基础免疫采用4周短间隔程序有可能提供更早的B群脑膜炎球菌病保护。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Timely vaccination is critical for providing early protection against meningococcal B (MenB) disease because of the high incidence in early childhood. We assessed the timeliness of vaccination in children with confirmed MenB disease after 4CMenB (a recombinant protein-based vaccine) implementation into the national infant immunisation programme in England. METHODS: Public Health England (PHE) conducts surveillance of invasive meningococcal disease (IMD) in England. Children born since 01 July 2015 who developed MenB disease between 01 September 2015 and 31 August 2019 (four surveillance years) were included in the analysis. RESULTS: There were 276 children with laboratory-confirmed MenB disease, including 36 infants who were too young for vaccination, 59 who were eligible for one 4CMenB dose, 104 for two doses and 77 for 3 doses before they developed MenB disease. Prior to developing MenB disease, there were 59 opportunities for vaccination with two 4CMenB doses in 48/104 (46.5%) eligible infants and 41 opportunities in 28/77 (36.6%) children aged ≥ 1 year who were under-immunised. A schedule with a shorter interval at 8 and 12 weeks of age, compared to the current schedule at 8 and 16 weeks, had the potential to offer an additional 4CMenB dose to 35/58 infants (58.6%) who developed MenB disease between 10 and 18 weeks of age. CONCLUSIONS: A high proportion of infants and toddlers with laboratory-confirmed MenB disease had not received their scheduled 4CMenB vaccine prior to developing MenB disease. An infant priming schedule with a shorter interval of 4 weeks has the potential to provide earlier protection against MenB disease.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ladhani SN, Campbell H, Amin-Chowdhury Z, et al. Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England. Vaccine. 2022. PMID: 35148913. doi:10.1016/j.vaccine.2021.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。